Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.19, $0.23 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $76.9 million versus the consensus estimate of $64.48 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.